Rivaroxaban for Antiphospholipid Antibody Syndrome (RAPS)
Rivaroxaban in Antiphospholipid Syndrome Pilot Study: A Multicenter Feasibility Study of Rivaroxaban for Patients With Antiphospholipid Syndrome and Prior Arterial or Venous Thrombosis
Sponsor: Bayer
A PHASE4 clinical study on Antiphospholipid Antibody Syndrome, this trial is completed. The trial is conducted by Bayer and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Aug 2017 — Nov 2017 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Hamilton Health Sciences Corporation
- Heart and Stroke Foundation of Canada
- Jewish General Hospital
- Queen Elizabeth II Health Sciences Centre
- St. Joseph's Healthcare Hamilton
- The Ottawa Hospital
- University of Alberta
For direct contact, visit the study record on ClinicalTrials.gov .